Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

OBJECTIVE: To evaluate the safety and efficacy of tocilizumab in clinical practice in patients with rheumatoid arthritis (RA) with inadequate responses (IR) to disease-modifying antirheumatic drugs (DMARDs) or both DMARDs and tumour necrosis factor α inhibitors (TNFis). METHODS: Patients—categorised...

Descripción completa

Detalles Bibliográficos
Autores principales: Bykerk, Vivian P, Östör, Andrew J K, Alvaro-Gracia, José, Pavelka, Karel, Ivorra, José Andrés Román, Graninger, Winfried, Bensen, William, Nurmohamed, Michael T, Krause, Andreas, Bernasconi, Corrado, Stancati, Andrea, Sibilia, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595980/
https://www.ncbi.nlm.nih.gov/pubmed/22615456
http://dx.doi.org/10.1136/annrheumdis-2011-201087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595980/
https://www.ncbi.nlm.nih.gov/pubmed/22615456
http://dx.doi.org/10.1136/annrheumdis-2011-201087

Ejemplares similares